...
首页> 外文期刊>Molecular pharmaceutics >Enhanced Generation of Cytotoxic T Lymphocytes by Heat Shock Protein 70 Fusion Proteins Harboring Both CD8~+ T Cell and CD4~+ T Cell Epitopes
【24h】

Enhanced Generation of Cytotoxic T Lymphocytes by Heat Shock Protein 70 Fusion Proteins Harboring Both CD8~+ T Cell and CD4~+ T Cell Epitopes

机译:通过带有CD8〜+ T细胞和CD4〜+ T细胞表位的热激蛋白70融合蛋白增强细胞毒性T淋巴细胞的生成

获取原文
获取原文并翻译 | 示例

摘要

Heat shock protein 70 (Hsp70) can be a potent carrier of antigens because it is effectively delivered to antigen presenting cells (APCs) and activates innate immunity. To induce a potent cytotoxic T lymphocyte (CTL) response, a Hsp70 fusion protein harboring both CD8+ and CD4~+ T cell epitopes was developed based on the recent understanding of the importance of the role of CD4~+ T cells in inducing the CTL response following vaccination. OVA257-264 (pepl) and OVA_(323)-339 (pepll) were selected as the CD8~+ and CD4~+ T cell epitope of a model antigen, ovalbumin (OVA), respectively. Hsp70 and its fusion proteins, Hsp70-pepl, pepll-Hsp70, Hsp70-pepll and pepll-Hsp70-pepl, were developed. pepll-Hsp70 and pepll-Hsp70-pepl were effectively presented on MHC class II of macrophages compared with Hsp70-pepll, suggesting that pepll conjugation to the N-terminus of Hsp70 is better than the C-terminus for more effective MHC class II antigen presentation. Immunization with pepll-Hsp70-pepl resulted in a higher CTL activity than immunization with the mixture of Hsp70-pepl and pepll-Hsp70. Furthermore, pepll-Hsp70-pepl exhibited a greater antitumor effect in the mice bearing EG7 tumor cells than the physical mixture of Hsp70-pepl and pepll-Hsp70. In addition, immunization with the DCs pulsed with the fusion proteins also suggested that APCs which present both pepl and pepll can induce the highest CTL generation. These results demonstrated that Hsp70 fusion protein harboring both pepl and pepll is a useful option for Hsp70-based antigen delivery systems.
机译:热休克蛋白70(Hsp70)可以是有效的抗原载体,因为它可以有效地传递到抗原呈递细胞(APC)并激活先天免疫。为了诱导强力的细胞毒性T淋巴细胞(CTL)反应,基于对CD4〜+ T细胞在诱导CTL反应中的作用的重要性的最新认识,开发了同时具有CD8 +和CD4〜+ T细胞表位的Hsp70融合蛋白。接种疫苗后。选择OVA257-264(pep1)和OVA_(323)-339(pepII)分别作为模型抗原卵清蛋白(OVA)的CD8 +和CD4 + + T细胞表位。开发了Hsp70及其融合蛋白Hsp70-pepl,pepll-Hsp70,Hsp70-pepll和pepll-Hsp70-pepl。与Hsp70-pepll相比,pepll-Hsp70和pepll-Hsp70-pepl有效地呈递于MHC II类巨噬细胞,这表明pepll与Hsp70的N末端结合比C末端更好,从而更有效地提供了MHC II类抗原。与用Hsp70-pepl和pepll-Hsp70的混合物进行免疫相比,用pepII-Hsp70-pepl进行免疫产生的CTL活性更高。此外,与带有Hsp70-pepl和pepll-Hsp70的物理混合物相比,pepll-Hsp70-pep1在带有EG7肿瘤细胞的小鼠中表现出更大的抗肿瘤作用。另外,用融合蛋白脉冲的DC免疫也表明,同时存在pepI和pepII的APC可以诱导最高的CTL产生。这些结果表明,同时具有pepl和pepII的Hsp70融合蛋白对于基于Hsp70的抗原递送系统是有用的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号